GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 37.11 | -53.21 | 10.53 | 33.37 | 34.38 |
| CEPS(Rs) | 54.33 | -44.26 | 17.00 | 52.46 | 50.10 |
| DPS(Rs) | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
| Book NAV/Share(Rs) | 313.28 | 277.46 | 335.13 | 321.45 | 249.60 |
| Tax Rate(%) | 25.16 | 5,116.71 | 137.34 | 31.06 | 29.83 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.01 | 4.31 | 5.79 | 8.35 | 8.26 |
| EBIT Margin(%) | 5.47 | 1.99 | 2.09 | 6.26 | 6.88 |
| Pre Tax Margin(%) | 4.77 | 0.13 | 0.85 | 5.18 | 5.48 |
| PAT Margin (%) | 3.57 | -6.61 | -0.32 | 3.57 | 3.84 |
| Cash Profit Margin (%) | 5.22 | -4.51 | 1.70 | 5.32 | 5.60 |
| Performance Ratios | |||||
| ROA(%) | 7.42 | -11.86 | -0.54 | 6.74 | 7.11 |
| ROE(%) | 12.56 | -21.18 | -0.97 | 12.33 | 14.81 |
| ROCE(%) | 16.16 | 4.88 | 4.43 | 14.19 | 15.30 |
| Asset Turnover(x) | 2.08 | 1.79 | 1.71 | 1.89 | 1.85 |
| Sales/Fixed Asset(x) | 2.94 | 2.77 | 2.74 | 2.94 | 2.97 |
| Working Capital/Sales(x) | 8.82 | 17.22 | 7.28 | 7.74 | 7.99 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.34 | 0.36 | 0.36 | 0.34 | 0.34 |
| Receivable days | 32.34 | 36.38 | 43.76 | 37.24 | 36.01 |
| Inventory Days | 34.46 | 32.19 | 31.52 | 31.35 | 31.90 |
| Payable days | 217.75 | 190.23 | 186.18 | 191.57 | 219.98 |
| Valuation Parameters | |||||
| PER(x) | 41.50 | - | 44.14 | 13.25 | 13.51 |
| PCE(x) | 28.35 | -21.63 | 27.36 | 8.43 | 9.27 |
| Price/Book(x) | 4.92 | 3.45 | 1.39 | 1.38 | 1.86 |
| Yield(%) | 0.16 | 0.26 | 0.54 | 0.57 | 0.54 |
| EV/Net Sales(x) | 3.30 | 2.23 | 1.41 | 1.20 | 1.52 |
| EV/Core EBITDA(x) | 17.83 | 12.95 | 8.48 | 5.93 | 7.80 |
| EV/EBIT(x) | 27.36 | 47.70 | 27.69 | 8.47 | 9.60 |
| EV/CE(x) | 3.98 | 2.98 | 1.18 | 0.96 | 1.18 |
| M Cap / Sales | 3.26 | 2.29 | 1.13 | 1.01 | 1.20 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 12.77 | 1.98 | -5.86 | 12.44 | 2.85 |
| Core EBITDA Growth(%) | 21.12 | 5.79 | -22.64 | 16.51 | 14.91 |
| EBIT Growth(%) | 190.75 | -6.18 | -66.14 | 0.22 | 17.80 |
| PAT Growth(%) | 157.19 | -1,944.25 | -109.01 | 2.43 | 25.02 |
| EPS Growth(%) | 169.73 | -605.16 | -68.44 | -2.92 | 25.01 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.25 | 0.13 | 0.46 | 0.40 | 0.67 |
| Current Ratio(x) | 1.56 | 1.28 | 1.85 | 1.77 | 1.75 |
| Quick Ratio(x) | 1.05 | 0.84 | 1.33 | 1.23 | 1.21 |
| Interest Cover(x) | 7.76 | 1.07 | 1.69 | 5.83 | 4.92 |
| Total Debt/Mcap(x) | 0.05 | 0.04 | 0.33 | 0.29 | 0.36 |
Compare Financial Ratios of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹54,209.2 Cr | 2.1% | 6% | 27.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,044.0 Cr | 1.5% | 6.5% | -1.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,877.0 Cr | 0.8% | 0.3% | 6.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹127,042.0 Cr | 1% | 4.4% | 18.1% | Stock Analytics | |
| CIPLA | ₹123,060.0 Cr | -0.4% | -3.8% | 1.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,190.0 Cr | 0.1% | -2.8% | 1.8% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 2.1% |
6% |
27.1% |
| SENSEX | 0.5% |
1.7% |
11% |
You may also like the below Video Courses
